Stanley Chen

VU Venture Partners is a global multi-stage and multi-sector venture capital fund with offices in San Francisco, Austin, and Hong Kong. VU Venture Partners owns and operates Venture University, an investor accelerator. Our teams focus on five core verticals: Consumer, Enterprise, Fintech, Frontier (Advanced AI, Robotics, Materials, SpaceTech), and Healthcare (Healthtech, Medical Devices, Pharma, BioTech)

Ideated, founded, and led original US based 15+ member cross-institutional team of computational biologists, biotechnology specialists, fertility specialists, and academics for early stages of venture creation, venture viability analysis of the healthcare, and initial strategic launch discovery in the in vitro fertilization (IVF) pre-implantation genetic analysis arena Led original technical development bioinformatics analysis pipeline involving Embryonic DNA Extraction, DNA Data Processing, Public Data Repository Comparative Analysis, and Advanced Bioinformatic Analyses Associated Organizations: Broad Institute, Novartis, Northwestern Medical CORE, NU-Seq Core Facility, multiple Fertility Clinics, and multiple Healthcare Systems

VCapital is proud to offer institutional-grade venture capital alternatives for family offices, accredited investors, and wealth advisors. VCapital is an experienced medium sized venture capital firm that has a proven management team that has never had a down decade in the past 30 years. VCapital is managed by one of the most experienced teams in the Midwest with a track record dating back to 1987. We are generally focused on providing the best investments into early-stage businesses whose potential has already been demonstrated through a successful angel/seed investment stage and that can, with additional capital, continue to grow, succeed, and deliver significant returns to our investors.

Continued research off the work of the 2017 Nobel Prize in Physiology or Medicine: Discovery of Molecular Mechanisms controlling the Circadian Rhythm Developed RNA based diagnostic Machine Learning models to detect Human Circadian Rhythm Disruption and diagnose an patient circadian time disruption using proprietary patient datasets comprised of over 600M+ time labelled gene expression datapoints, 7000+ genes, and 70+ subjects

Connecticut Innovations (CI) is a quasi-state entity that acts as the Venture Capital Investments arm of the State of Connecticut. CI operates an evergreen fund that invests in Tech, Healthcare, ClimateTech, AI, and more

Gen 1 Capital is a deep tech focused venture fund based out of Chicago, IL that invests in founders transforming our world and impacting future generations

Supported 15+ founders at the earliest stages of commercialization. Investor pitch deck optimization, development of customer feedback loops, and early stage venture viability analysis. Over $100,000 in capital raised/transactions Pitch deck optimization, pre-seed fundraising, preparation for pitch competitions, alumni fundraising, and alumni outreach across New York, Boston, and San Francisco as a member of the inaugural class of Werth Innovators Generously funded by the Werth Institute

Led 4 person commercial viability evaluation team for the venture viability of a new innovative drug delivery and bone repair technology spin out from the University of Connecticut School of Medicine Researched, developed, and presented findings/analyses culminating in 6 internal industry reports/presentations in multiple areas of venture viability research: Market Needs Specification Report, Technical Concept Analysis, Competitor Analysis, Intellectual Property Report, and Business Plan Outline

Led team of 3 fellows to track, monitor, and analyze the competitive landscape of 50+ early-stage pharmaceutical companies pursuing pipeline development of a treatment and/or cure for Non-Alcoholic-Fatty Liver Disease (NAFLD/NASH) and applications in Cancer Related Therapeutic commercialization Developed and maintained biweekly presentations presenting newly published findings of technology advances in competitors: competitor pipeline development advancements, new investments, and new market shifts/trends

Advisors: Ravi Allada, Arthur Felse, and Igor Kourkine Minor: Graduate Entrepreneurship Focus Areas: Circadian Rhythm Disruption, Advanced RNAseq Analysis, Bioprocess Engineering, Machine Learning, Synthetic Biology, Antisense Oligonucleotides, and Nanoplasmonic Sensors

Minor: Technology Innovation and Entrepreneurship Focus Areas: Commercial Potential of Cellulose Scaffolds in Surgical Bone Repair, Ozone Based Pathogen Elimination in Upadhyay Laboratory, and Ecofriendly Oxoammonium Catalysts in Leadbeater Laboratory